

Express Mail No.: EL 501 638 875 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Siegall *et al.*

Application No.: 09/328,296

Group Art Unit: 1642

Filed: June 8, 1999

Examiner: K. Canella

For: RECOMBINANT ANTI-CD40 ANTIBODY
AND USES THEREOF

Attorney Docket No.: 9632-005

FEE TRANSMITTAL SHEET

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$603.

The claim amendment fee has been estimated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		SMALL ENTITY		OTHER THAN A SMALL ENTITY	
CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO PREVIOUSLY PAID FOR		PRESENT EXTRA		RATE	ADDIT. FEE	RATE	ADDIT. FEE
TOTAL	113	MINUS	52	=	67	× 9	\$ 603.00	× 18	\$
INDEP.	12	MINUS	26	=	0	× 40	\$ 0.00	× 80	\$
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM						135	\$	270	\$
						TOTAL	\$ 603.00	OR TOTAL	\$

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,


Date April 18, 2001

Adriane M. Antler 32,605
Adriane M. Antler (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure

04/23/2001 MABD11 00000058 161150 09328296
01 FC:203 603.00 CH



Off-20-8
Express Mail No.: EL 501 638 875 US
1642
E/11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: SIEGALL ET AL.

Serial No.: 09/328,296

Examiner: K. Canella

Filed: June 8, 1999

Group Art Unit: 1642

For: RECOMBINANT ANTI-CD40 ANTIBODY AND
USES THEREOF Attorney Docket No.: 9632-005

AMENDMENT UNDER 37 C.F.R. § 1.111

RECEIVED

APR 25 2001

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

S I R:

In response to the outstanding Office Action dated October 18, 2000, please enter the following amendments and consider the following remarks. Applicants submit concurrently herewith:

- (1) Exhibit A, containing marked up versions of the amended paragraphs;
- (2) Exhibit B, containing marked up versions of the amended claims;
- (3) Exhibit C, containing a copy of the claims as will be pending upon entry of the instant amendments;
- (4) Exhibit D, a Declaration of Dr. Joseph A. Francisco under 37 C.F.R. § 1.132, with Exhibits 1-5¹;
- (5) Exhibit E, a copy of Glaser *et al.*, 1992, J. Immunol.149:3903-13;
- (6) Exhibit F, a copy of Yelton *et al.*, 1995, J. Immunol. 155:1994-2004;
- (7) Exhibit G, a copy of Wu *et al.*, 1998, Proc. Natl. Acad. Sci. U.S.A. 95:6037-42;
- (8) Exhibit H, a copy of Barbas *et al.*, 1994, Proc. Natl. Acad. Sci. U.S.A. 91:3809-3813;
- (9) Exhibit I, a copy of Schier *et al.*, 1996, J. Mol. Biol. 263:551-567
- (10) Exhibit J, a copy of Foote and Winter, 1992, J. Mol. Biol. 224:487-499;

¹The Declaration submitted herewith is unexecuted; an executed Declaration will be filed at the earliest opportunity.